BVF as of June 30, 2024
Portfolio Holdings for BVF
BVF holds 60 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 26.8 | $956M | 22M | 43.97 | |
| Revolution Medicines (RVMD) | 6.5 | $232M | 6.0M | 38.81 | |
| Kymera Therapeutics (KYMR) | 4.3 | $154M | 5.2M | 29.85 | |
| Ionis Pharmaceuticals (IONS) | 4.3 | $152M | 3.2M | 47.66 | |
| Mirum Pharmaceuticals (MIRM) | 4.2 | $149M | 4.4M | 34.19 | |
| Gh Research Ordinary Shares (GHRS) | 3.4 | $121M | 10M | 11.66 | |
| Protagonist Therapeutics (PTGX) | 3.2 | $115M | 3.3M | 34.65 | |
| Cullinan Oncology (CGEM) | 2.8 | $100M | 5.8M | 17.44 | |
| Olema Pharmaceuticals (OLMA) | 2.8 | $99M | 9.1M | 10.82 | |
| Structure Therapeutics Sponsored Ads (GPCR) | 2.7 | $98M | 2.5M | 39.27 | |
| Xoma Corp Del Com New (XOMA) | 2.4 | $86M | 3.6M | 23.69 | |
| Kura Oncology (KURA) | 2.4 | $84M | 4.1M | 20.59 | |
| 4d Molecular Therapeutics In (FDMT) | 2.3 | $82M | 3.9M | 20.99 | |
| Axsome Therapeutics (AXSM) | 2.2 | $77M | 955k | 80.50 | |
| Cg Oncology (CGON) | 2.1 | $76M | 2.4M | 31.57 | |
| Merus N V (MRUS) | 2.1 | $76M | 1.3M | 59.17 | |
| Ac Immune Sa SHS (ACIU) | 2.1 | $75M | 19M | 3.99 | |
| Tyra Biosciences (TYRA) | 2.1 | $75M | 4.7M | 15.99 | |
| 89bio (ETNB) | 1.7 | $61M | 7.6M | 8.01 | |
| Celcuity (CELC) | 1.6 | $57M | 3.5M | 16.38 | |
| Third Harmonic Bio (THRD) | 1.6 | $57M | 4.4M | 13.00 | |
| Agios Pharmaceuticals (AGIO) | 1.4 | $51M | 1.2M | 43.12 | |
| Zymeworks Del (ZYME) | 1.4 | $50M | 5.9M | 8.51 | |
| Essa Pharma Com New (EPIX) | 1.3 | $46M | 8.7M | 5.26 | |
| Ideaya Biosciences (IDYA) | 1.1 | $41M | 1.2M | 35.11 | |
| Galapagos Nv Spon Adr (GLPG) | 1.1 | $39M | 1.6M | 24.78 | |
| Annexon (ANNX) | 1.0 | $34M | 7.0M | 4.90 | |
| Repare Therapeutics Ord | 1.0 | $34M | 10M | 3.30 | |
| Foghorn Therapeutics (FHTX) | 0.9 | $31M | 5.3M | 5.75 | |
| Calliditas Therapeutics Ab Sponsered Ads | 0.8 | $29M | 750k | 38.99 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.8 | $29M | 1.5M | 19.21 | |
| Roivant Sciences SHS (ROIV) | 0.8 | $29M | 2.7M | 10.57 | |
| Engene Holdings (ENGN) | 0.6 | $21M | 2.3M | 9.43 | |
| Janux Therapeutics (JANX) | 0.5 | $19M | 442k | 41.89 | |
| Tscan Therapeutics (TCRX) | 0.5 | $18M | 3.0M | 5.85 | |
| Eledon Pharmaceuticals (ELDN) | 0.5 | $17M | 6.3M | 2.64 | |
| Allakos | 0.5 | $17M | 17M | 1.00 | |
| Immunic (IMUX) | 0.3 | $9.9M | 8.9M | 1.11 | |
| Ikena Oncology (IKNA) | 0.2 | $7.9M | 4.8M | 1.65 | |
| Vigil Neuroscience (VIGL) | 0.2 | $7.3M | 1.8M | 4.00 | |
| Vistagen Therapeutics Ord (VTGN) | 0.2 | $7.0M | 2.0M | 3.48 | |
| Cytomx Therapeutics (CTMX) | 0.2 | $6.4M | 5.2M | 1.22 | |
| Elevation Oncology (ELEV) | 0.2 | $6.2M | 2.3M | 2.70 | |
| Verastem Com New (VSTM) | 0.1 | $5.0M | 1.7M | 2.98 | |
| Cidara Therapeutics Com New (CDTX) | 0.1 | $4.1M | 343k | 11.94 | |
| Verve Therapeutics (VERV) | 0.1 | $3.2M | 650k | 4.88 | |
| Molecular Partners Ads (MOLN) | 0.1 | $3.2M | 443k | 7.15 | |
| Ovid Therapeutics (OVID) | 0.1 | $3.0M | 3.9M | 0.77 | |
| Sab Biotherapeutics Com New (SABS) | 0.1 | $2.8M | 918k | 3.10 | |
| Glycomimetics | 0.1 | $2.7M | 9.5M | 0.28 | |
| Pieris Pharmaceuticals Com New | 0.1 | $2.5M | 258k | 9.88 | |
| Inventiva Sa Ads (IVA) | 0.1 | $2.0M | 686k | 2.95 | |
| Viracta Therapeutics (VIRX) | 0.1 | $2.0M | 3.6M | 0.54 | |
| Forte Biosciences | 0.0 | $1.6M | 3.0M | 0.54 | |
| Engene Holdings *w Exp 10/31/202 (ENGNW) | 0.0 | $1.3M | 945k | 1.39 | |
| Nls Pharmaceutics SHS | 0.0 | $1.2M | 5.7M | 0.22 | |
| Unicycive Therapeutics | 0.0 | $1.1M | 2.2M | 0.50 | |
| Rezolute Com New (RZLT) | 0.0 | $821k | 191k | 4.30 | |
| Molecular Templates Com New (MTEMQ) | 0.0 | $601k | 522k | 1.15 | |
| Aslan Pharmaceuticals Spon Ads New (ASLN) | 0.0 | $315k | 1.0M | 0.30 |
